CD84 is markedly up‐regulated in Kawasaki disease arteriopathy

Summary The major goals of Kawasaki disease (KD) therapy are to reduce inflammation and prevent thrombosis in the coronary arteries (CA), but some children do not respond to currently available non‐specific therapies. New treatments have been difficult to develop because the molecular pathogenesis is unknown. In order to identify dysregulated gene expression in KD CA, we performed high‐throughput RNA sequencing on KD and control CA, validated potentially dysregulated genes by real‐time reverse transcription–polymerase chain reaction (RT–PCR) and localized protein expression by immunohistochemistry. Signalling lymphocyte activation molecule CD84 was up‐regulated 16‐fold (P